insights_auto
Nega CRSP tushdi 3,65%?
Batafsil oʻrganishchevron_right
CRSP:NASDAQ
Crispr Therapeutics AG
50,44 US$
arrow_downward
-3,65%(-1,91) 1K
50,60 US$
arrow_upward
+0,32% (+0,16)bedtimeYopilgandan keyin
Savdolar yopilgan: 8-okt, 16:00:01 (GMT-4) · USD
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoCRSP tikeri uchun statistika yaratilmoqda...
Ochish
51,51 US$
Yuqori
53,54 US$
Past
50,02 US$
Bozor kapitali
4,88 mlrd
Oʻrtacha hajm
1,56 mln
Hajmi
0,00
52 haftalik eng yuqori
78,34 US$
52 haftalik eng past
44,12 US$
Aksiya boʻyicha daromad
-4,76 US$
Beta
1,45
Muomaladagi aksiyalar
96,69 mln
Xodimlar soni
393
Ochish
51,51 US$
Yuqori
53,54 US$
Past
50,02 US$
Bozor kapitali
4,88 mlrd
Oʻrtacha hajm
1,56 mln
Hajmi
0,00
52 haftalik eng yuqori
78,34 US$
52 haftalik eng past
44,12 US$
Aksiya boʻyicha daromad
-4,76 US$
Beta
1,45
Muomaladagi aksiyalar
96,69 mln
Xodimlar soni
393
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
MarketBeat
·
23 daqiqa oldin
CRISPR Therapeutics AG (NASDAQ:CRSP) Stock Rated "Moderate Buy" by Sell-Side Brokerages
Investing.com Canada
·
9 soat oldin
Form 4 CRISPR Therapeutics AG For: 8 October By Investing.com
Stock Titan
·
9 soat oldin
Counsel exercises options and sells 1,990 CRISPR Therapeutics (CRSP) shares under a trading plan.
Zacks
·
15 soat oldin
AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer
Profil
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023. Wikipedia
Crispr Therapeutics AG haqida
CEOSamarth Kulkarni
Xodimlar soni393
Asos solingan2013
Bosh ofislarZug, Zug, Shveytsariya
Sektor-
Veb-saytcrisprtx.com